Compare Novartis AG (NVS) vs Vanguard Tax Managed Fund FTSE Developed Markets ETF (VEA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Vanguard Tax Managed Fund FTSE Developed Markets ETF — how do they compare? Novartis AG trades at $153.82 (market cap $298.18B), while Vanguard Tax Managed Fund FTSE Developed Markets ETF trades at $72.71. The key difference: Novartis AG pays a 3.02% dividend while Vanguard Tax Managed Fund FTSE Developed Markets ETF pays none, and Vanguard Tax Managed Fund FTSE Developed Markets ETF is trading nearer its 52-week high, Novartis AG nearer its low. Which is the better fit depends on your goals.
| NVS | VEA | |
|---|---|---|
Market Cap | $298.18B | — |
Sector | Health | — |
52-Week High | $168.62 | $72.89 |
52-Week Low | $119.31 | $58.19 |
Enterprise Value | $339.50B | — |
Dividend Yield | 3.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.
The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.
VEA trades at $72.89, up 1.07% today, with a bullish technical outlook supported by moving averages. The ETF focuses on developed markets outside the U.S., offering low-cost diversification. Recent news highlights mixed institutional activity, with some firms increasing stakes while others reduce holdings, reflecting varied sentiment toward international equity exposure.
The outlook for VEA is supported by its low expense ratio and diversification benefits, but risks include currency fluctuations and geopolitical tensions in developed markets. Analyst comparisons favor VEA for cost efficiency, though performance relative to U.S. indices remains a key consideration for investors seeking global allocation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Vanguard Tax Managed Fund FTSE Developed Markets ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Developed All Cap ex US Index, a market-capitalization-weighted index that is made up of approximately 4022 common stocks of large-, mid-, and small-cap companies located in Canada and the major markets of Europe and the Pacific region. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VEA →
